Grants and Contracts Details
Description
Leukemia stem cells (LSCs) are a small population of malignant cells known to initiate and maintain leukemia. LSCs
have been identified for AML, CML and ALL. Unfortunately, there is increasing evidence demonstrating that LSCs are
not effectively destroyed by standard chemotherapy regimens. Failure to eradicate LSCs is likely to result in disease
relapse. Therefore, novel therapies that can destroy LSCs are urgently needed to prevent relapse and improve patient
survival. We have identified a compound [4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)] that can induce
rapid and irreversible cell death in leukemia cells including progenitor and stem cell populations without harming normal
blood cells. TDZD-S has been previously studied for cell protective functions in animal models for treatment of different
diseases including Alzheimer's, colitis and stroke. However, we have identified a unique anti-leukemia effect for this
agent that can be observed with a very short exposure to the drug (5-30 minutes). Therefore, the objective of this proposal
is to study and improve the properties ofTDZD-8 for leukemia therapy.
Status | Finished |
---|---|
Effective start/end date | 10/1/07 → 9/30/08 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.